Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007340
Chunk: 30

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 30
---
 Pre-Funded Warrants, and the December 2023 Underwriter Warrants.

Exercisability.
The warrants became exercisable on December 21, 2023. The Series E Warrants and December 2023Underwriter
Warrants expire five years and three years, respectively from the initial exercise date. The December 2023 Private Placement Pre-Funded Warrants are exercisable at any time and do not expire. The holder shall deliver the aggregate
exercise price for the Depositary Shares specified in the exercise notice within two trading days following the date of exercise (subject
to the ‘cashless exercise’ arrangements described below).

Cashless Exercise. If, at the time a holder exercises its Series E Warrants, a registration statement registering the issuance of
the securities underlying the Series E Warrants under the Securities Act is not then effective or available and an exemption from
registration under the Securities Act is not available for the issuance of such shares, then in lieu of making the cash payment otherwise
contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon
such exercise (either in whole or in part) the net number of Depositary Shares determined according to a formula set forth in the Series E
Warrants.

At
the time a holder exercises its December 2023 Private Placement Pre-Funded Warrants,
in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price,
the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of Depositary Shares determined
according to a formula set forth in the December 2023 Private Placement Pre-Funded
Warrants.

| 21 |

Exercise Price.The exercise price of each Series E Warrant, December 2023Underwriter Warrant, and December 2023 Private Placement Pre-Funded
Warrant is $55.00, $62.50 and $0.0025 per Depositary Share.

Beneficial Ownership Limitation. A holder shall have no right to exercise any portion of a warrant, to the extent that, after giving effect
to such exercise, such holder, together with such holder’s affiliates, and any persons acting as a group together with such holder
or any such affiliate, would beneficially own in excess of 9.99% (or in the case of the December 2023Underwriter Warrants, 4.99%), of the number